I realized this week that Feb. 12 was the 3rd anniversary of the approval of ibrutinib in the USA that changed the whole treatment landscape in CLL, so I thought I would reflect on all the progress thathas taken place in the treatment of our disease during this time frame and all the issues that still remain. You can read my thoughts and share yourown here: http://cllsociety.org/2017/02/reflections-three-year-anniversary/
What a wild and wonderful three years it has been- but we are not over the finish line quite yet.
Stay strong.
We are all in this together.
Brian
http://cllsociety.orgIf you want a personal response, or just want to stay in touch, please email me at [email protected]. I have no other way of contacting. Thanks. Stay strong. After all, we are all in this together. And please visit our website: http://cllsociety.org for the latest news and information.
Community Magazine
Author's Latest Articles
-
A Matching-Adjusted Indirect Comparison of Acalabrutinib Vs. Zanubrutinib in Relapsed Or Refractory CLL
-
My Personal Decision to Restart My CLL (chronic Lymphocytic Leukemia) Treatment
-
ASH 2022: Adverse Events from BTK Inhibitors in Clinical Trials
-
Dr. Stephan Stilgenbauer on the Evolution of CLL to Richter’s Syndrome from ASH 2022